Vergent Bioscience, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-20.
Vergent Bioscience, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 20, 2025. The filing reports $18.67M sold. Its industry group is Biotechnology. It names John Santini, Jr. (Executive Officer, Director), Douglas Kohrs (Director), Raymond Wong (Director) (SEC Form D, October 20, 2025).
Is this your company?
Sell to companies like Vergent Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Vergent Bioscience, Inc.
Free to see. No signup.
More on the people and the money behind Vergent Bioscience, Inc., from the filings we hold.
Biotechnology raises by companies based in Minnesota, filed within 90 days of this one, largest first.
Get an email when Vergent Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Vergent Bioscience, Inc. raises, hires or launches. No email unless you switch it on.
Watch Vergent Bioscience, Inc. →Get the full cited report on Vergent Bioscience, Inc.
What the filing shows about Vergent Bioscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vergent Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Vergent Bioscience, Inc.'s address as 5810 W 78TH St, Ste 222, Minneapolis, MN 55439.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Vergent Bioscience, Inc. See pricing
Vergent Bioscience, Inc. is a registered filer with the SEC (CIK 1741495) and has filed since 2022-10-04. 4 filings are on record, the latest on 2025-10-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Vergent Bioscience, Inc.'s Form D of 2025-10-20 names John Santini, Jr., Douglas Kohrs, Raymond Wong and 3 more as its officers, directors or promoters.
Its new offerings report $43.97M sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Vergent Bioscience’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all solid tumor tissue is removed.
The title and description the site itself served, answering 200, after redirecting from https://vergentbio.com. Not a cached copy and not the company's directory entry — what was live when we asked.
John Santini, Jr. is named as Executive Officer and Director on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
Douglas Kohrs is named as Director on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
Raymond Wong is named as Director on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
Bobby Helmedag is named as Director on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
Anita Watkins is named as Director on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
Jeffrey Yurecko is named as Executive Officer on the Form D that Vergent Bioscience, Inc. filed with the SEC on 20 October 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-10-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Vergent Bioscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vergent Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vergent Bioscience, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Vergent Bioscience, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Vergent Bioscience, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (vergentbio.com).
Each opens in a new tab, filled in for Vergent Bioscience, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Minneapolis-St. Paul
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/vergent-bioscience-inc-form-d-25000001